Treatment indications
HepaGam B® Hepatitis B Immune Globulin Intravenous (Human) is indicated for the prevention of hepatitis B recurrence following liver transplant in HBsAg positive liver transplant patients.

HepaGam B® is also indicated in the event of:
  • Acute exposure to blood containing HBsAg
  • Perinatal exposure of infants born to HBsAg-positive mothers
  • Sexual exposure to HBsAg-positive people
  • Household exposure to people with acute HBV infection
    • Household exposure of infants less than 12 months old whose mother or primary care giver is positive for HBsAg



For more information on HepaGam B®,
please contact Apotex at 877-HepaGam B (437-2426).

Press Release
December 19, 2008 - Announcing a change in NDC numbers for HepaGam B®

HepaGam B® (Hepatitis B Immune Globulin Intravenous (Human)), is a purified gamma globulin (IgG) fraction of human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Individuals known to have severe, potentially life-threatening reactions to human globulin should not receive HepaGam B® or any other immune globulin (Human). Individuals who are deficient in IgA may have the potential for developing IgA antibodies and have severe, potentially life-threatening allergic reactions. The maltose contained in HepaGam B® can interfere with some types of blood glucose monitoring systems. Only testing Systems that are glucose-specific should be used in patients receiving HepaGam B®. This interference can result in Falsely elevated glucose readings that can lead to untreated hypoglycemia or to inappropriate insulin administration, resulting In life-threatening hypoglycemia. The most common expected adverse drug reactions for immune globulins like HepaGam B® are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.